You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Alpha-1 Antitrypsin Gene Therapy for Cystic Fibrosis

    SBC: Generx+, Inc.            Topic: N/A

    DESCRIPTION (Applicant's Abstract): The investigators have developed a plasmid vector that expresses the normal human alpha-1 antitrypsin (AAT) gene in human respiratory epithelium when delivered as a plasmid-cationic liposome complex. In subjects with inherited AAT deficiency, they showed that liposome mediated transfer of the normal AAT gene to the nasal respiratory epi ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  2. An Advanced Biosensor for Molecular Interaction Studies.

    SBC: MOLECULAR SENSING, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Molecular interactions form the foundation of biology and chemistry. They are central to life itself and determine catalytic activity, cellular function, and therapeutic efficacy. The vast majority of diagnostic procedures depend on some type of specific molecular interaction. Therefore, the ability to perform pure liquid-phase molecular binding analysis at hi ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. A Novel Apoptosis Assay with Antibodies to ssDNA

    SBC: APOSTAIN, INC.            Topic: N/A

    DESCRIPTION (Provided by Applicant): Work performed during the Phase I of this project has demonstrated that formamide induces selective denaturation of DNA in apoptotic cells. This novel effect of formamide on the stability of apoptotic DNA combined with the detection of denatured DNA with monoclonal antibody (MAb)against single-stranded DNA, has made it possi ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  4. A Novel Apoptosis Assay with Antibodies to ssDNA

    SBC: APOSTAIN, INC.            Topic: N/A

    DESCRIPTION (Provided by Applicant): Work performed during the Phase I of this project has demonstrated that formamide induces selective denaturation of DNA in apoptotic cells. This novel effect of formamide on the stability of apoptotic DNA combined with the detection of denatured DNA with monoclonal antibody (MAb)against single-stranded DNA, has made it possi ...

    STTR Phase II 2001 Department of Health and Human ServicesNational Institutes of Health
  5. Audio-Vestibular Testing for Bedside/Other Applications

    SBC: INTELLIGENT HEARING SYSTEMS CORP            Topic: N/A

    DESCRIPTION: (Adapted from applicant's abstract): A potentially effective way of limiting or preventing drug-induced cochleo- and vestibulo-ototoxicity is monitoring during treatment. However, practical, cost-effective, monitoring programs are difficult to establish due to impractical instrumentation. Current practices also tend to neglect the balance system. Research ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  6. Audio-Vestibular Testing for Bedside/Other Applications

    SBC: INTELLIGENT HEARING SYSTEMS CORP            Topic: N/A

    DESCRIPTION: (Adapted from applicant's abstract): A potentially effective way of limiting or preventing drug-induced cochleo- and vestibulo-ototoxicity is monitoring during treatment. However, practical, cost-effective, monitoring programs are difficult to establish due to impractical instrumentation. Current practices also tend to neglect the balance system. Research ...

    STTR Phase II 2001 Department of Health and Human ServicesNational Institutes of Health
  7. Automated Monitoring of Chemotactic Cell Movement

    SBC: APPLIED BIOPHYSICS, INC.            Topic: N/A

    DESCRIPTION ( provided by applicant): The ECIS/taxis technology can detect cells that move to a small electrode through an agarose matrix by the resistance that they impart to an electrical circuit as they cover parts of the small electrode. This system is amenable to rapid throughput analysis of cell behavior in the presence of chemokines and other agents that ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  8. Automated Monitoring of Chemotactic Cell Movement

    SBC: APPLIED BIOPHYSICS, INC.            Topic: N/A

    DESCRIPTION ( provided by applicant): The ECIS/taxis technology can detect cells that move to a small electrode through an agarose matrix by the resistance that they impart to an electrical circuit as they cover parts of the small electrode. This system is amenable to rapid throughput analysis of cell behavior in the presence of chemokines and other agents that ...

    STTR Phase II 2001 Department of Health and Human ServicesNational Institutes of Health
  9. Better GaN substrates through HVPE on bulk AlN substrates

    SBC: Crystal IS, Inc.            Topic: N/A

    Single-crystal aluminum nitride substrates will be used for epitaxial growth of GaN by hydride vapor phase epitaxy (HVPE). The relatively close match in crystal structure, in chemical compatibility, and in thermal expansion should allow much high quality(and much thicker) GaN layers to be grown. HVPE will allow these GaN epitaxial layers to grown cost effectively.Extremely high power microwave ...

    STTR Phase I 2001 Department of DefenseMissile Defense Agency
  10. Clinical Translation of an Anti-Metastatic Antibody for Breast Cancer Therapy

    SBC: FOR-ROBIN, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): This proposal aims to develop a novel, highly-specific targeted therapy for treatment of breast cancer. The long-term objective is to convert the proprietary intellectual property, the mouse monoclonal antibody (McAb)JAA-F11, which targets the pancarcinoma Thomsen-Friedenreich antigen (TF-Ag) to a humanized form for use as an adjunct with conventional therapy ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government